Johns Hopkins Medicine offers one of the few fully accredited comprehensive cancer centers in the country and the first in our geographic region. Because of this special status we are able to offer patients a variety of clinical trial programs that can provide the latest advancements in clinical care and treatment for breast cancer. Oftentimes patients associate clinical trials solely with chemotherapy regimens.
Latest research 07 Feb The past twelve months were a fruitful time for breast cancer research. We hope the discoveries being made will provide hope and inspiration to all those living with breast cancer, and to the 17, women and men expected to be diagnosed in
Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer.
Breast cancer treatments must be personalised to each individual. Our research aims to improve treatment options and ensure all patients can access the right treatment for them. Our research into new treatments has changed the landscape for breast cancer patients. Now, we must develop treatments that are highly targeted and as unique as each individual patient, ensure all patients can access the right treatment for them and that everyone living with and beyond breast cancer receives the support they need.
This is an exciting time in metastatic breast cancer research. Many new treatments for metastatic breast cancer are under study and treatment is improving. Findings from clinical trials will determine whether or not new treatments will become a part of standard care for metastatic breast cancer.
NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat breast cancer. They are also looking at how to address disparities and improve quality of life for survivors of the disease. MRI magnetic resonance imagingultrasoundand clinical breast exams are also used to detect breast cancer, but not as routine screening tools.
A new form of drug drastically improves survival rates of younger women with the most common type of breast cancer, researchers said on Saturday, citing the results of an international clinical trial. The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that the addition of cell-cycle inhibitor ribociclib increased survival rates to 70 percent after three and a half years. The mortality rate was 29 percent less than when patients, all under 59 and pre-menopausal, were randomly assigned a placebo.
Scientists have used artificial intelligence to recognise patterns in breast cancer -- and uncovered five new types of the disease each matched to different personalised treatments. Their study applied AI and machine learning to gene sequences and molecular data from breast tumours, to reveal crucial differences among cancers that had previously been lumped into one type. The new study, led by a team at The Institute of Cancer Research, London, found that two of the types were more likely to respond to immunotherapy than others, while one was more likely to relapse on tamoxifen. The researchers are now developing tests for these types of breast cancer that will be used to select patients for different drugs in clinical trials, with the aim of making personalised therapy a standard part of treatment.
Skip to Content. Use the menu to see other pages. Doctors are working to learn more about early-stage and locally advanced breast cancer, including ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials.